Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Nat Commun. 2021 May 3;12(1):2487. doi: 10.1038/s41467-021-22582-6.
Nat Commun. 2021.
PMID: 33941784
Free PMC article.
Clinical Trial.